JP2022515198A - FGFRチロシンキナーゼの阻害剤としての置換ピラゾロ[1,5-a]ピリジン化合物 - Google Patents

FGFRチロシンキナーゼの阻害剤としての置換ピラゾロ[1,5-a]ピリジン化合物 Download PDF

Info

Publication number
JP2022515198A
JP2022515198A JP2021536038A JP2021536038A JP2022515198A JP 2022515198 A JP2022515198 A JP 2022515198A JP 2021536038 A JP2021536038 A JP 2021536038A JP 2021536038 A JP2021536038 A JP 2021536038A JP 2022515198 A JP2022515198 A JP 2022515198A
Authority
JP
Japan
Prior art keywords
fgfr
cancer
ring
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021536038A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022515198A5 (cg-RX-API-DMAC7.html
Inventor
エフ ブレイク,ジェイムズ
エイ モレノ,デイビッド
レン,リィ
ピー タン,トニー
エム ウォールズ,シェイン
Original Assignee
アレイ バイオファーマ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレイ バイオファーマ インコーポレイテッド filed Critical アレイ バイオファーマ インコーポレイテッド
Publication of JP2022515198A publication Critical patent/JP2022515198A/ja
Publication of JP2022515198A5 publication Critical patent/JP2022515198A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021536038A 2018-12-19 2019-12-13 FGFRチロシンキナーゼの阻害剤としての置換ピラゾロ[1,5-a]ピリジン化合物 Ceased JP2022515198A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862781990P 2018-12-19 2018-12-19
US62/781,990 2018-12-19
PCT/US2019/066278 WO2020131627A1 (en) 2018-12-19 2019-12-13 Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases

Publications (2)

Publication Number Publication Date
JP2022515198A true JP2022515198A (ja) 2022-02-17
JP2022515198A5 JP2022515198A5 (cg-RX-API-DMAC7.html) 2022-12-20

Family

ID=69160414

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021536038A Ceased JP2022515198A (ja) 2018-12-19 2019-12-13 FGFRチロシンキナーゼの阻害剤としての置換ピラゾロ[1,5-a]ピリジン化合物

Country Status (5)

Country Link
US (1) US12180207B2 (cg-RX-API-DMAC7.html)
EP (1) EP3898626A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022515198A (cg-RX-API-DMAC7.html)
CN (1) CN113490666A (cg-RX-API-DMAC7.html)
WO (1) WO2020131627A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025005042A1 (ja) * 2023-06-27 2025-01-02 東京応化工業株式会社 レジスト組成物、レジストパターン形成方法、化合物及び高分子化合物
JP2025515466A (ja) * 2022-04-25 2025-05-15 イーライ リリー アンド カンパニー Fgfr2阻害剤化合物
JP2025531794A (ja) * 2022-09-07 2025-09-25 イーライ リリー アンド カンパニー がんの治療のためのFGFR3阻害剤としてのピラゾロ[1,5-a]ピリジン及びイミダゾ[1,2-a]ピリジン誘導体

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2876689C (en) 2012-06-13 2022-04-26 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CA2976790C (en) 2015-02-20 2024-02-27 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
KR102956194B1 (ko) 2018-05-04 2026-04-23 인사이트 코포레이션 Fgfr 억제제의 염
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
MX2022006691A (es) 2019-12-04 2022-09-19 Incyte Corp Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021213476A1 (zh) * 2020-04-22 2021-10-28 深圳晶泰科技有限公司 一种吡唑并[1,5-a]吡啶类衍生物及其制备方法,组合物以及用途
US20230321087A1 (en) * 2020-09-14 2023-10-12 Janssen Pharmaceutica Nv Fgfr inhibitor combination therapies
EP4244223A1 (en) * 2020-11-13 2023-09-20 Biogen MA Inc. Pyrazolo[1,5-a]pyrazine derivatives as btk inhibitors
KR20230142745A (ko) 2021-01-29 2023-10-11 세딜라 테라퓨틱스, 인크. Cdk2 억제제 및 그의 사용 방법
AR125588A1 (es) * 2021-03-04 2023-08-02 Lilly Co Eli Compuestos inhibidores de fgfr3
TW202304889A (zh) * 2021-04-03 2023-02-01 大陸商海南耀臻生物醫藥科技有限公司 作為fgfr抑制劑的雜環化合物及其應用
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為fgfr抑制劑之三環雜環
US20240287081A1 (en) * 2021-06-09 2024-08-29 Icahn School Of Medicine At Mount Sinai Perfluoroalkane substituted pyrazolo[3,4-d]pyrimidin and pyrrolo[2,3-d]pyrimidin compounds and uses thereof
TW202317560A (zh) 2021-06-26 2023-05-01 美商賽迪拉治療股份有限公司 Cdk2抑制劑及其使用方法
CN115772170B (zh) * 2021-12-03 2025-05-16 徐诺药业(南京)有限公司 一种吡唑并[1,5-a]吡啶衍生物及其制备方法和应用
US12662483B2 (en) * 2022-09-07 2026-06-23 Eli Lilly And Company Cocrystalline forms of FGFR3 inhibitors
CN120051471A (zh) * 2022-10-18 2025-05-27 首药控股(北京)股份有限公司 一种新型杂环化合物
WO2024109799A1 (zh) * 2022-11-22 2024-05-30 西藏海思科制药有限公司 一种嘧啶衍生物及其在医药上的应用
WO2024137587A1 (en) * 2022-12-19 2024-06-27 Tyra Biosciences, Inc. Fgfr3 inhibitor compounds
WO2024151638A2 (en) * 2023-01-10 2024-07-18 Cogent Biosciences, Inc. Compounds for fgfrs inhibitors
WO2024182447A1 (en) * 2023-02-28 2024-09-06 Vividion Therapeutics, Inc. Compounds and methods for modulating ras-pi3k
TW202442224A (zh) * 2023-03-20 2024-11-01 香港商英矽智能科技知識產權有限公司 Fgfr2與fgfr3之抑制劑及其用途
CN122270275A (zh) 2023-08-07 2026-06-23 科景特生物科学公司 用于fgfr抑制的化合物
CN122319146A (zh) * 2023-11-16 2026-06-30 首药控股(北京)股份有限公司 一种新型杂环化合物
CN117802079B (zh) * 2023-12-29 2026-01-27 柯泰亚生物科技(上海)有限公司 一种瓦伦烯合酶突变体及其应用
CN119258066B (zh) * 2024-10-14 2025-07-04 暨南大学附属第一医院(广州华侨医院) Alw-ii-41-27在治疗眼科疾病中的新应用
GB202416727D0 (en) * 2024-11-13 2024-12-25 Imperial College Innovations Ltd RAB27 inhibitors

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011530511A (ja) * 2008-08-05 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション 治療用化合物
JP2012180344A (ja) * 2011-02-07 2012-09-20 Chugai Pharmaceut Co Ltd アミノピラゾール誘導体を含む医薬
WO2015108992A1 (en) * 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
JP2015523383A (ja) * 2012-07-11 2015-08-13 ブループリント メディシンズ コーポレイション 線維芽細胞成長因子受容体の阻害剤
JP2016530274A (ja) * 2013-08-23 2016-09-29 ニューファーマ, インコーポレイテッド ある特定の化学的実体、組成物および方法
WO2018040885A1 (zh) * 2016-09-01 2018-03-08 南京药捷安康生物科技有限公司 成纤维细胞生长因子受体抑制剂及其用途
WO2018113584A1 (zh) * 2016-12-19 2018-06-28 上海和誉生物医药科技有限公司 Fgfr4抑制剂、其制备方法与药学上的应用

Family Cites Families (206)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4304777A (en) 1979-08-30 1981-12-08 Sterling Drug Inc. 6-(Pyridinyl)-3(2H)-pyridazinones and their use as cardiotonics
US4305943A (en) 1980-04-28 1981-12-15 Sterling Drug Inc. 4-Amino-6-(pyridinyl)-3(2H)-pyridazinones and their use as cardiotonics
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4826835A (en) 1985-10-23 1989-05-02 Rorer Pharmaceutical Corporation Pyridyl-pyridazinone and pyridyl-pyrazolinone compounds and their use in the treatment of congestive heart failure
WO1989008108A1 (en) 1988-02-23 1989-09-08 Rorer International (Overseas) Inc. Pyridyl-pyridazinone and pyridyl-pyrazolinone compounds and their use in the treatment of congestive heart failure
DE69025946T2 (de) 1989-09-08 1996-10-17 Univ Duke Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
DE4127404A1 (de) 1991-08-19 1993-02-25 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5844092A (en) 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
PT706799E (pt) 1994-09-16 2002-05-31 Merck Patent Gmbh Imunoconjugados ii
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
PL188959B1 (pl) 1995-07-06 2005-05-31 Novartis Ag Pirolopirymidyny i sposoby ich wytwarzania
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
CN100503580C (zh) 1996-04-12 2009-06-24 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂
US6391874B1 (en) 1996-07-13 2002-05-21 Smithkline Beecham Corporation Fused heterocyclic compounds as protein tyrosine kinase inhibitors
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
CN1160338C (zh) 1998-11-19 2004-08-04 沃尼尔·朗伯公司 N-[4-(3-氯-4-氟-苯基氨基)-7-(3-吗啉-4-基-丙氧基)-喹唑啉-6-基]-丙烯酰胺,不可逆的酪氨酸激酶抑制剂
IL153375A0 (en) 2000-06-22 2003-07-06 Genentech Inc Agonist anti-trk-c monoclonal antibodies
WO2004022540A2 (en) 2002-09-06 2004-03-18 Fujisawa Pharmaceutical Co., Ltd. Pyridazinone and pyridone derivatives as adenosine antagonists
ES2325440T3 (es) 2003-02-20 2009-09-04 Smithkline Beecham Corporation Compuestos de pirimidina.
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
WO2005099363A2 (en) 2004-03-26 2005-10-27 Whitehead Institute For Biomedical Research Methods of diagnosing, preventing and treating cancer metastasis
EP1737841A1 (en) 2004-04-01 2007-01-03 Astellas Pharma Inc. Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists
US7696352B2 (en) 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
PE20060664A1 (es) 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
US20080090827A1 (en) 2004-11-30 2008-04-17 Artesian Therapeutics, Inc. Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure
DE102005003687A1 (de) 2005-01-26 2006-07-27 Sphingo Tec Gmbh Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation
CA2608009A1 (en) 2005-05-16 2006-11-23 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
MY153898A (en) 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
KR101379693B1 (ko) 2005-08-25 2014-04-10 크리어빌리스 쎄라퓨틱스 에스.피.에이. K-252a 및 그의 유도체의 중합체 컨쥬게이트
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
AU2006325746A1 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
RS55630B1 (sr) 2005-12-21 2017-06-30 Janssen Pharmaceutica Nv Triazolopiridazini kao modulatori tirozin kinaze
ZA200808966B (en) 2006-03-27 2010-03-31 Nerviano Medical Sciences Srl Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors
US20110008347A1 (en) 2006-12-01 2011-01-13 Agency For Science ,Technology And Research Cancer-related protein kinases
RU2009122670A (ru) 2006-12-21 2011-01-27 Плекссикон, Инк. (Us) Соединения и способы для модуляции киназ и показания к их применению
WO2008079909A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
CN101679408B (zh) 2006-12-22 2016-04-27 Astex治疗学有限公司 作为fgfr抑制剂的双环杂环化合物
EA200900821A1 (ru) 2006-12-22 2010-02-26 Новартис Аг Производные 1-аминометил-l-фенилциклогексана как ингибиторы дпп-iv (дипептидилпептидазы-iv)
BRPI0811516A2 (pt) 2007-05-04 2014-11-18 Irm Llc Compostos e composições como inibidores de c-kit e pdgfr cinase
DE102007025717A1 (de) 2007-06-01 2008-12-11 Merck Patent Gmbh Arylether-pyridazinonderivate
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
EP2740731B1 (en) 2007-06-13 2016-03-23 Incyte Holdings Corporation Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
EP2170894A1 (en) 2007-06-21 2010-04-07 Janssen Pharmaceutica N.V. Polymorphic and hydrate forms, salts and process for preparing 6-{difluoro[6-(1-methyl-1h-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline
JP2010533158A (ja) 2007-07-09 2010-10-21 アストラゼネカ アクチボラグ 化合物類−945
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン,インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
BRPI0814441A2 (pt) 2007-07-19 2015-07-14 Schering Corp Compostos de amida heterocíclica como inibidores de proteína cinase
EA018503B1 (ru) 2007-07-20 2013-08-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Замещенные производные индазола, активные как ингибиторы киназы
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
KR20100089851A (ko) 2007-10-23 2010-08-12 노파르티스 아게 호흡기 질환의 치료를 위한 trkb 항체의 용도
EP2215091B1 (en) 2007-12-04 2016-03-30 Nerviano Medical Sciences S.r.l. Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
JP5420568B2 (ja) 2008-01-17 2014-02-19 アイアールエム・リミテッド・ライアビリティ・カンパニー 改良された抗TrkB抗体
EP2254886B1 (en) 2008-03-28 2016-05-25 Nerviano Medical Sciences S.r.l. 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
CA2723237A1 (en) 2008-05-06 2009-11-12 Peter A. Blomgren Substituted amides, method of making, and use as btk inhibitors
US8158636B2 (en) 2008-05-19 2012-04-17 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
PE20091846A1 (es) 2008-05-19 2009-12-16 Plexxikon Inc DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
EP2328586A2 (en) 2008-05-20 2011-06-08 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
AU2009248774B2 (en) 2008-05-23 2012-05-31 Novartis Ag Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
CN104530052A (zh) 2008-06-10 2015-04-22 普莱希科公司 用于激酶调节的5h-吡咯[2,3-b]吡嗪衍生物和其适应症
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
JP2010013369A (ja) 2008-07-01 2010-01-21 Astellas Pharma Inc ピラジン誘導体の製造法
CN102105151B (zh) 2008-07-29 2013-12-18 内尔维阿诺医学科学有限公司 Cdk抑制剂在治疗神经胶质瘤中的应用
US8394802B2 (en) 2008-09-19 2013-03-12 Nerviano Medical Sciences S.R.L. 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one derivatives for the modulation of the activity of protein kinases
SI2350075T1 (sl) 2008-09-22 2014-06-30 Array Biopharma, Inc. Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji
CN102264736B (zh) 2008-10-22 2013-08-14 阵列生物制药公司 作为TRK激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物
WO2010056875A1 (en) 2008-11-12 2010-05-20 Cgi Pharmaceuticals, Inc. Pyridazinones and their use as btk inhibitors
US8912194B2 (en) 2008-11-24 2014-12-16 Nerviano Medical Sciences S.R.L. CDK inhibitor for the treatment of mesothelioma
PT2370413E (pt) 2008-12-08 2015-10-23 Arena Pharm Inc Moduladores do recetor da prostaciclina (pgi2) úteis para o tratamento de distúrbios relacionados com o mesmo
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
WO2010083283A2 (en) 2009-01-15 2010-07-22 Incyte Corporation Processes for preparing jak inhibitors and related intermediate compounds
WO2010111527A1 (en) 2009-03-26 2010-09-30 Plexxikon, Inc. Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use
BRPI1012108B8 (pt) 2009-05-22 2021-05-25 Incyte Corp composto 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octa no- ou heptano-nitrila, sua composição, seus usos e processo para preparar um sal de ácido fosfórico
EP3045457B1 (en) 2009-06-15 2018-05-09 Nerviano Medical Sciences S.r.l. Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
KR20120063515A (ko) 2009-09-09 2012-06-15 아빌라 테라퓨틱스, 인크. Pi3 키나제 억제제 및 이들의 용도
EA021478B1 (ru) 2009-10-09 2015-06-30 Инсайт Корпорейшн ГИДРОКСИЛЬНЫЕ, КЕТО И ГЛЮКУРОНИДНЫЕ ПРОИЗВОДНЫЕ 3-(4-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1Н-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
KR101483215B1 (ko) 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
WO2011092120A1 (en) 2010-01-29 2011-08-04 Nerviano Medical Sciences S.R.L. 6,7- dihydroimidazo [1,5-a] pyrazin-8 (5h) - one derivatives as protein kinase modulators
ES2594927T3 (es) 2010-02-18 2016-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Métodos para prevenir las metástasis cancerosas
TWI510487B (zh) 2010-04-21 2015-12-01 Plexxikon Inc 用於激酶調節的化合物和方法及其適應症
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
BR122019024201B1 (pt) 2010-05-20 2021-08-03 Array Biopharma Inc Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
EP2668188B1 (en) 2011-01-26 2016-05-18 Nerviano Medical Sciences S.r.l. Tricyclic derivatives, process for their preparation and their use as kinase inhibitors
US8975267B2 (en) 2011-01-26 2015-03-10 Nerviano Medical Sciences S.R.L. Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors
PE20141360A1 (es) 2011-02-07 2014-10-13 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas e indicaciones para los mismos.
US9199979B2 (en) 2011-02-24 2015-12-01 Nerviano Medical Sciences S.R.L. Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors
BR112013021638A2 (pt) 2011-02-25 2016-08-02 Irm Llc "compostos inibidores de trk, seu uso e composições que os compreendem"
US9284298B2 (en) 2011-04-11 2016-03-15 Nerviano Medical Sciences S.R.L. Pyrazolyl-pyrimidine derivatives as kinase inhibitors
RU2621732C2 (ru) 2011-04-19 2017-06-07 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Замещенные пиримидинилпирролы, активные в качестве ингибиторов киназы
EA023579B1 (ru) 2011-05-12 2016-06-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Замещенные производные индазола, активные в качестве ингибиторов киназы
NZ618795A (en) 2011-05-13 2015-07-31 Array Biopharma Inc Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
EP2736514B1 (en) 2011-07-28 2017-10-18 Nerviano Medical Sciences S.r.l. Alkynyl substituted pyrimidinyl-pyrroles active as kinases inhibitors
JP6036693B2 (ja) 2011-08-05 2016-11-30 アステラス製薬株式会社 新規fgfr4変異体の検出法
KR20140052032A (ko) 2011-08-17 2014-05-02 에프. 호프만-라 로슈 아게 브루톤 티로신 키나아제의 억제제
ES2660265T3 (es) 2011-10-07 2018-03-21 Nerviano Medical Sciences S.R.L. Derivados de 3,4-dihidropirrolo[1,2-a]pirazin-1(2h)-ona 4-alquil-sustituidos como inhibidores de cinasa
WO2013050446A1 (en) 2011-10-07 2013-04-11 Nerviano Medical Sciences S.R.L. SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-a]PYRAZIN-1(2H)-ONE DERIVATIVES AS KINASES INHIBITORS
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
US8669251B2 (en) 2011-11-03 2014-03-11 Genentech, Inc. 8-fluorophthalazin-1(2H)-one compounds
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
AU2012339753A1 (en) 2011-11-14 2014-06-19 Tesaro, Inc. Modulating certain tyrosine kinases
US9133328B2 (en) 2011-12-12 2015-09-15 Sa Des Eaux Minerales D'evian Saeme Plastic compositions and containers made thereof
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
PE20150666A1 (es) 2012-03-01 2015-05-06 Array Biopharma Inc Inhibidores de serina/treonina cinasa
ES2605388T3 (es) 2012-04-26 2017-03-14 Ono Pharmaceutical Co., Ltd. Compuesto inhibidor de Trk
US9254288B2 (en) 2012-05-07 2016-02-09 The Translational Genomics Research Institute Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
NZ703124A (en) 2012-05-23 2016-07-29 Nerviano Medical Sciences Srl Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
TWI585088B (zh) 2012-06-04 2017-06-01 第一三共股份有限公司 作爲激酶抑制劑之咪唑并[1,2-b]嗒衍生物
CA2876689C (en) 2012-06-13 2022-04-26 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
BR112015001724A2 (pt) 2012-07-27 2018-04-03 Genentech Inc métodos de tratamento de condições relacionadas a fgfr3
CN104507923B (zh) 2012-08-02 2018-02-09 内尔维阿诺医学科学有限公司 作为激酶抑制剂的取代的吡咯类活性剂
EP4223770A3 (en) 2012-11-05 2023-10-18 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
EP2917214B1 (en) 2012-11-07 2019-08-28 Nerviano Medical Sciences S.r.l. Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors
WO2014078325A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9822118B2 (en) 2012-11-13 2017-11-21 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078372A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078417A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078331A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078328A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
ME02990B (me) 2012-11-13 2018-10-20 Array Biopharma Inc Jedinjenja n-pirolidinil, n'-pirazolil- uree, tiouree, guanidina i cijanoguanidina kао inhibitori trka kinaze
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
CA2891334C (en) 2012-11-13 2021-10-19 Array Biopharma Inc. Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain
US9981959B2 (en) 2012-11-13 2018-05-29 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
MX2015004626A (es) 2012-11-29 2015-07-14 Yeda Res & Dev Metodos para prevenir metastasis de tumor, tratar y pronosticar cancer e identificar agentes que son inhibidores putativos de metastasis.
CA2898326C (en) 2013-01-18 2022-05-17 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
JP6483624B2 (ja) 2013-02-07 2019-03-13 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung ピリダジノン−アミド誘導体
MX362181B (es) 2013-02-19 2019-01-08 Ono Pharmaceutical Co Compuesto inhibidor de cinasa del receptor de tropomiosina (trk).
JP2016510751A (ja) 2013-03-06 2016-04-11 ジェネンテック, インコーポレイテッド 抗がん剤耐性を治療及び予防する方法
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
US9850038B2 (en) 2013-03-15 2017-12-26 Reynolds Presto Products Inc. Child resistant zipper closure for recloseable pouch with double slider and methods
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
CN105431436B (zh) 2013-05-14 2017-11-28 内尔维阿诺医学科学有限公司 吡咯并[2,3‑d]嘧啶衍生物,它们的制备方法和它们作为激酶抑制剂的用途
RU2015149937A (ru) 2013-05-30 2017-07-06 Плексксикон Инк. Соединения для модулирования киназы и показания к их применению
HK1214820A1 (zh) 2013-07-03 2016-08-05 豪夫迈.罗氏有限公司 杂芳基吡啶酮和氮杂-吡啶酮酰胺化合物
JP6084292B2 (ja) 2013-07-18 2017-02-22 大鵬薬品工業株式会社 Fgfr阻害剤耐性癌の治療薬
EP3628749A1 (en) 2013-07-30 2020-04-01 Blueprint Medicines Corporation Ntrk2 fusions
WO2015017528A1 (en) 2013-07-30 2015-02-05 Blueprint Medicines Corporation Pik3c2g fusions
US10323285B2 (en) 2013-09-09 2019-06-18 Nantomics, Llc Proteomics analysis and discovery through DNA and RNA sequencing, systems and methods
RU2650512C2 (ru) 2013-09-18 2018-04-16 Бейджин Ханми Фармасьютикал Ко., Лтд. Соединение, ингибирующее активности киназ ВТК и/или JAK3
CN105792844B (zh) 2013-10-08 2021-03-02 第一三共株式会社 抗fgfr2抗体和另一药剂的组合
US9334263B2 (en) 2013-10-17 2016-05-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
MX365614B (es) 2013-10-17 2019-06-07 Blueprint Medicines Corp Composiciones utiles para tratar trastornos relacionados con kit.
PT3395814T (pt) 2013-10-25 2022-07-27 Blueprint Medicines Corp Inibidores do recetor do fator de crescimento de fibroblastos
CN105793251B (zh) 2013-12-05 2018-10-12 豪夫迈·罗氏有限公司 具有亲电子官能性的杂芳基吡啶酮和氮杂-吡啶酮化合物
EP3089970B1 (en) 2013-12-09 2018-10-17 AbbVie Inc. Dihydropyridinone and dihydropyridazinone derivatives useful as bromodomain inhibitors
IL274464B2 (en) 2013-12-11 2023-08-01 Accuragen Holdings Ltd Preparations and methods for the detection of rare sequence variants
WO2015099127A1 (ja) 2013-12-27 2015-07-02 中外製薬株式会社 Fgfrゲートキーパー変異遺伝子およびそれを標的とする医薬
CN103772352B (zh) 2014-01-16 2017-01-18 四川百利药业有限责任公司 哒嗪酮类衍生物及其制备方法和用途
WO2015112806A2 (en) 2014-01-24 2015-07-30 Tp Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
US20160340742A1 (en) 2014-02-04 2016-11-24 Mayo Foundation For Medical Education And Research Method of Identifying Tyrosine Kinase Receptor Rearrangements in Patients
DK3102577T3 (en) 2014-02-07 2018-11-12 Principia Biopharma Inc QUINOLONDERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
US11037129B1 (en) 2014-02-24 2021-06-15 Groupon, Inc. Consumer device presence-based transaction session
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
BR112016022056B1 (pt) 2014-03-26 2023-04-11 Astex Therapeutics Limited Combinação, composição farmacêutica, uso de uma combinação ou uma composição farmacêutica, e, produto farmacêutico
WO2015150900A2 (en) 2014-03-31 2015-10-08 Debiopharm International Sa Fgfr fusions
WO2015160636A1 (en) 2014-04-16 2015-10-22 Merck Sharp & Dohme Corp. Factor ixa inhibitors
WO2015160634A1 (en) 2014-04-16 2015-10-22 Merck Sharp & Dohme Corp. Factor ixa inhibitors
WO2015161274A1 (en) 2014-04-18 2015-10-22 Blueprint Medicines Corporation Pik3ca fusions
US20170044621A1 (en) 2014-04-18 2017-02-16 Blueprint Medicines Corporation Met fusions
CN106459013B (zh) 2014-05-15 2019-10-25 阵列生物制药公司 作为trka激酶抑制剂的化合物及其用途
EA028614B1 (ru) 2014-05-22 2017-12-29 Общество С Ограниченной Ответственностью "Русские Фармацевтические Технологии" Селективные ингибиторы, нарушающие взаимодействие рецептора фактора роста фибробластов и frs2, для профилактики и лечения рака
EP3155131B1 (en) 2014-06-10 2020-02-12 Blueprint Medicines Corporation Raf1 fusions
WO2015191667A1 (en) 2014-06-10 2015-12-17 Blueprint Medicines Corporation Pkn1 fusions
WO2015193740A2 (en) 2014-06-17 2015-12-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor
US10370724B2 (en) 2014-07-17 2019-08-06 Blueprint Medicines Corporation PRKC fusions
EP3169804B3 (en) 2014-07-17 2019-09-18 Blueprint Medicines Corporation Fgr fusions
WO2016011144A1 (en) 2014-07-17 2016-01-21 Blueprint Medicines Corporation Tert fusions
US9688680B2 (en) 2014-08-04 2017-06-27 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
HUE045237T2 (hu) 2014-08-18 2019-12-30 Ono Pharmaceutical Co TRK-inhibitáló vegyület savaddíciós sója
CN107427524A (zh) 2014-08-28 2017-12-01 翁科埃斯克斯有限公司 利用包含噻吩并三唑并二氮杂*化合物的药物组合物治疗急性髓细胞白血病或急性淋巴性白血病的方法
JP6636014B2 (ja) 2014-09-12 2020-01-29 ノバルティス アーゲー Rafキナーゼ阻害剤としての化合物および組成物
EP3218378B1 (en) 2014-11-14 2020-01-08 Nerviano Medical Sciences S.r.l. 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
TWI746426B (zh) 2014-11-16 2021-11-21 美商亞雷生物製藥股份有限公司 (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型
US20170356052A1 (en) 2014-11-18 2017-12-14 Blueprint Medicines Corporation Prkacb fusions
JP2018027019A (ja) 2014-11-26 2018-02-22 国立研究開発法人国立がん研究センター 胆道がんにおける新規治療標的融合遺伝子
AU2015371312B2 (en) 2014-12-24 2022-01-27 Genentech, Inc. Therapeutic, diagnostic and prognostic methods for cancer of the bladder
US9909016B2 (en) 2015-02-28 2018-03-06 Matthew Fontaine Elastomeric coating composition
WO2016139227A1 (en) 2015-03-03 2016-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Fgfr3 antagonists
US10538517B2 (en) 2015-05-22 2020-01-21 Principia Biopharma, Inc. Quinolone derivatives as FGFR inhibitors
EP3355808B1 (en) 2015-10-02 2022-11-16 Flexdex, Inc. Handle mechanism providing unlimited roll
EP3365335B1 (en) 2015-10-23 2024-02-14 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
US9640210B1 (en) 2015-11-13 2017-05-02 Kabushiki Kaisha Toshiba Virtual window mode for guide spiral servo demodulation
CN108082275B (zh) 2016-11-23 2021-08-24 操纵技术Ip控股公司 电动转向系统
MA47408B1 (fr) 2017-12-20 2023-08-31 Janssen Pharmaceutica Nv Traitement du cancer

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011530511A (ja) * 2008-08-05 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション 治療用化合物
JP2012180344A (ja) * 2011-02-07 2012-09-20 Chugai Pharmaceut Co Ltd アミノピラゾール誘導体を含む医薬
JP2015523383A (ja) * 2012-07-11 2015-08-13 ブループリント メディシンズ コーポレイション 線維芽細胞成長因子受容体の阻害剤
JP2016530274A (ja) * 2013-08-23 2016-09-29 ニューファーマ, インコーポレイテッド ある特定の化学的実体、組成物および方法
WO2015108992A1 (en) * 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
WO2018040885A1 (zh) * 2016-09-01 2018-03-08 南京药捷安康生物科技有限公司 成纤维细胞生长因子受体抑制剂及其用途
WO2018113584A1 (zh) * 2016-12-19 2018-06-28 上海和誉生物医药科技有限公司 Fgfr4抑制剂、其制备方法与药学上的应用

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025515466A (ja) * 2022-04-25 2025-05-15 イーライ リリー アンド カンパニー Fgfr2阻害剤化合物
JP2025531794A (ja) * 2022-09-07 2025-09-25 イーライ リリー アンド カンパニー がんの治療のためのFGFR3阻害剤としてのピラゾロ[1,5-a]ピリジン及びイミダゾ[1,2-a]ピリジン誘導体
WO2025005042A1 (ja) * 2023-06-27 2025-01-02 東京応化工業株式会社 レジスト組成物、レジストパターン形成方法、化合物及び高分子化合物

Also Published As

Publication number Publication date
EP3898626A1 (en) 2021-10-27
US12180207B2 (en) 2024-12-31
WO2020131627A1 (en) 2020-06-25
US20220081438A1 (en) 2022-03-17
CN113490666A (zh) 2021-10-08

Similar Documents

Publication Publication Date Title
US12180207B2 (en) Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases
US12351571B2 (en) Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases
US11851434B2 (en) Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors
JP6945070B2 (ja) 結晶形態
JP7060694B2 (ja) Retキナーゼ阻害剤としての置換ピロロ[2,3-d]ピリミジン化合物
US10174027B2 (en) Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
JP6997876B2 (ja) Retキナーゼ阻害剤としての置換ピラゾリル[4,3-c]ピリジン化合物
JP2022062168A (ja) Retキナーゼ阻害剤としての置換ピラゾロ[1,5-a]ピリジン化合物
JP7061195B2 (ja) RETキナーゼ阻害剤としての置換ピラゾロ[3,4-d]ピリミジン化合物
JP2020536895A (ja) 6−(2−ヒドロキシ−2−メチルプロポキシ)−4−(6−(6−((6−メトキシピリジン−3−イル)メチル)−3,6−ジアザビシクロ[3.1.1]ヘプタン−3−イル)ピリジン−3−イル)ピラゾロ[1,5−a]ピリジン−3−カルボニトリルを含む製剤
MD3523302T2 (ro) Compuși pirazolo[1,5-a]piridină substituiți în calitate de inhibitori ai RET kinazei
JP2022500383A (ja) Retキナーゼ阻害剤としての縮合複素環式化合物
JP7808616B2 (ja) 環式化合物及びそれを使用する方法
HK40060210A (en) Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
HK40060213A (en) 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221212

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240122

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240402

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20240827